학술논문
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Document Type
Article
Author
Source
In: The Lancet . (The Lancet, 12 - 18 October 2019, 394(10206):1352-1363)
Subject
Language
English
ISSN
1474547X
01406736
01406736